FDA Expands Approval for Keytruda in Locally Advanced Cutaneous SCC

The U.S. Food and Drug Administration (FDA) has decided to expand approval for Merck’s anti-PD-1 monotherapy KEYTRUDA for locally advanced cutaneous squamous cell carcinoma (cSCC) not curable by radiation or surgery.